1. Home >
  2. Aisling Capital, Apax and EW Healthcare Partners Invest In Xanodyne Pharmaceuticals

Investment Summary

Aisling Capital, Apax and EW Healthcare Partners Invest In Xanodyne Pharmaceuticals

On July 18, 2005, private equity firm Aisling Capital, private equity firm Apax and growth capital firm EW Healthcare Partners invested in medical products company Xanodyne Pharmaceuticals

Investment Highlights
  • This is Aisling Capital’s 1st, Apax’s 5th and EW Healthcare Partners’ 8th transaction in the Medical Products sector.
  • This is Aisling Capital’s 3rd, Apax’s 35th and EW Healthcare Partners’ 16th transaction in the United States.
  • This is Aisling Capital’s 1st, Apax’s 1st and EW Healthcare Partners’ 1st transaction in Kentucky.

Investment Summary
Date 2005-07-18
Target Xanodyne Pharmaceuticals
Sector Medical Products
Investor(s) Aisling Capital
Apax
EW Healthcare Partners
Deal Type Venture

Target

Xanodyne Pharmaceuticals

Newport, Kentucky, United States
Xanodyne Pharmaceuticals is a fully integrated, branded specialty pharmaceutical company focusing on innovative products in the therapeutic areas of women?s health and pain management.

Search 204,425 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Investor(S) 3

Investor

Aisling Capital

New York, New York, United States

Investor Investor Investor Investor Investor

Category Private Equity Firm
Founded 2000
PE ASSETS 1.8B USD
Size Large
Type Sector Focused
DESCRIPTION

Aisling Capital is a private investment firm focused on opportunities in the healthcare and medical technology sectors. The Firm specifically looks to invest in companies developing and commercializing innovative healthcare products, services, and technologies. Aisling Capital looks to commit $20 to $50 million per investment and prefers to be the lead investor. Aisling will consider investing in both public and private companies. Aisling Capital raised its first fund in 2000. The Firm is based in New York City.

DEAL STATS #
Overall 3 of 56
Sector (Medical Products) 1 of 7
Type (Venture) 2 of 29
State (Kentucky) 1 of 1
Country (United States) 3 of 52
Year (2005) 1 of 1
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2004-03-26 Myogen

Westminster, Colorado, United States

Myogen is a Development stage biotechnology company focused on cardiovascular drugs. Myogen has two product candidates in late-stage clinical development: ambrisentan for the treatment of patients with pulmonary arterial hypertension (PAH) and darusentan for the treatment of patients with resistant hypertension.

Sell -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2006-01-02 ARMGO Pharma

Tarrytown, New York, United States

ARMGO Pharma is a biopharmaceutical company dedicated to the discovery and development of novel small-molecule therapeutics to treat debilitating cardiac, muscular, and neurological disorders. ARMGO Pharma is based in Tarrytown, New York.

Buy -
Investor

Apax

London, United Kingdom

Investor Investor

Category Private Equity Firm
Founded 1981
PE ASSETS 77.0B USD
Size Mega
Type Sector Agnostic
DESCRIPTION

Apax Partners is a mega-sized private equity investment group, operating across the United States, Europe, Israel and Asia. Broad industry sectors of interest include tech & telecom, media, retail & consumer, healthcare, financial services, and business services. Apax will consider both minority and majority investment positions and prefers companies with strong market positions and growth potential. The Firm generally pursues platform acquisitions valued from $1 to $5 billion. Apax Partners was formed in 1981 and is based in London.

DEAL STATS #
Overall 83 of 264
Sector (Medical Products) 5 of 10
Type (Venture) 26 of 34
State (Kentucky) 1 of 1
Country (United States) 35 of 106
Year (2005) 11 of 18
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2005-07-18 Versatel AG

Berlin, Germany

Versatel AG is a provider of infrastructure based telecommunications services in the German market.

Buy €565M
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2005-08-17 Transera Communication

Sunnyvale, California, United States

Transera Communication, Inc. is a provider of cloud based contact center software for small-medium business (SMB) and large enterprises.

Buy -
Investor

EW Healthcare Partners

Category Growth Capital Firm
Founded 1985
PE ASSETS 3.0B USD
Size Large
Type Sector Focused
DESCRIPTION

Essex Woodlands Health Ventures is a growth equity and venture capital specialist investment firm focused on opportunities across the healthcare sector. Specific areas of interest include biotechnology, pharmaceuticals, medical devices, and healthcare services/IT. Historically, Essex invested primarily in early and later-stage situations; however, today the firm also makes growth capital investments between $20 - $60 million in companies valued between $50 - $250 million, as well as private investments in public entities (PIPEs). Essex Woodlands was formed in 1985 and offices in Palo Alto, California; New York City; Houston, Texas; Shanghai and London.

DEAL STATS #
Overall 17 of 59
Sector (Medical Products) 8 of 24
Type (Venture) 15 of 32
State (Kentucky) 1 of 1
Country (United States) 16 of 50
Year (2005) 3 of 4
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2005-07-06 Dow Pharmaceutical Sciences

Petaluma, California, United States

Developer, manufacturer and marketer as well as formulator of topical therapies focused on the dermatology market.

Buy -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2005-10-12 Light Sciences Oncology

Bellevue, Washington, United States

Light Sciences Oncology has developed an innovative, practical, targeted therapy that can destroy previously untreatable tumors. Its therapeutic platform combines the best-in-class light-activated drug and novel light generation devices to destroy tumors from the inside out.

Buy -
Mergr

Product

Company

Legal